American Century Companies Inc. Has $458.21 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• American Century Companies Inc. increased its stake in Regeneron Pharmaceuticals by 2.1%, now owning approximately 0.66% of the company valued at $458.2 million.
• Regeneron Pharmaceuticals reported a Q2 EPS of $12.89, significantly exceeding analysts' expectations, with revenues of $3.68 billion, marking a 3.6% increase year-over-year.
• The company declared a quarterly dividend of $0.88 per share, reflecting an annualized yield of 0.6%, with the ex-dividend date set for August 18th.

American Century Companies Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 722,467 shares of the biopharmaceutical company's stock after buying an additional 14,921 shares during the quarter. American Century Companies Inc. owned about 0.66% of Regeneron Pharmaceuticals worth $458,211,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Capital International Investors grew its holdings in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. GAMMA Investing LLC grew its holdings in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the period. Nuveen LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $343,764,000. Finally, Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.4%

REGN traded down $2.13 during trading on Tuesday, hitting $571.78. The company's stock had a trading volume of 854,199 shares, compared to its average volume of 1,109,170. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock's fifty day moving average price is $545.33 and its 200-day moving average price is $593.59. The firm has a market capitalization of $60.60 billion, a P/E ratio of 14.41, a PEG ratio of 1.93 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the company earned $11.56 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Finally, BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.